Fulgent Genetics (FLGT) Capital Expenditures (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Capital Expenditures data on file, last reported at $5.2 million in Q1 2026.

• Quarterly Capital Expenditures rose 10.26% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.1 million (down 43.73% YoY) and the FY2025 annual result came in at $22.6 million, down 44.01% from the prior year.
• Capital Expenditures slipped to $5.2 million in Q1 2026 per FLGT's latest filing, from $20.5 million in the prior quarter.
• The five-year high for Capital Expenditures was $37.8 million in Q4 2024, with the low at -$2.3 million in Q3 2024.
• Average Capital Expenditures over 5 years is $6.4 million, with a median of $4.7 million recorded in 2025.
• Year-over-year, Capital Expenditures soared 1117.87% in 2024 and plunged 393.95% in 2025.
• Fulgent Genetics' Capital Expenditures stood at $4.7 million in 2022, then sank by 34.22% to $3.1 million in 2023, then soared by 1117.87% to $37.8 million in 2024, then slumped by 45.8% to $20.5 million in 2025, then plunged by 74.63% to $5.2 million in 2026.
• Business Quant data shows FLGT's Capital Expenditures at $5.2 million in Q1 2026, $20.5 million in Q4 2025, and -$510000.0 in Q3 2025.